Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

UNUM Therapeutics

UNUM Therapeutics
2014 FOUNDED
PUBLIC STATUS
51-60 EMPLOYEES
UMRX STOCK SYMBOL
$3.48 SHARE PRICE (As of Wednesday Closing)
Description

Unum Therapeutics Inc is an US based clinical-stage biopharmaceutical company. it is focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer.

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 200 Cambridge Park Drive
  • Suite 3100
  • Cambridge, MA 02140
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore UNUM Therapeutics’s full profile, request a free trial.

UNUM Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$3.03 - $17.66 $105M $3.43 -$1.31 88K 30.1M

UNUM Therapeutics Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 53,505 140,532
Revenue 10,567 9,734 8,360 6,355
EBITDA (39,373) (34,364) (24,707) (17,559)
Net Income (39,488) (34,532) (25,492) (18,124)
Total Assets 81,280 85,927 49,115 75,550
Public Fundamental Data provided by Morningstar, Inc. disclaimer

UNUM Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore UNUM Therapeutics‘s full profile, request access.

Request full access to PitchBook

UNUM Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore UNUM Therapeutics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

UNUM Therapeutics Competitors (38)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000000 00000
0000 000000000000 Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
000000000000 Venture Capital-Backed Houston, TX 000.00 00000000000 000.00
000 0000000000000 Private Equity-Backed Saint Asaph, United Kingdom 00 000.00 0000000 0000 000.00
0000000 00000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
To view this company’s complete list of competitors, request access »

UNUM Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore UNUM Therapeutics‘s full profile, request access.

Request full access to PitchBook

UNUM Therapeutics Executive Team (5)

Name Title Board
Seat
Contact
Info
Charles Wilson Ph.D Co-Founder, Board Member & Chief Executive Officer
Christiana Stamoulis Chief Financial Officer & President
Geoffrey Hodge Chief Technology Officer
Seth Ettenberg Ph.D Chief Scientific Officer
Michael Vasconcelles MD Chief Medical Officer

UNUM Therapeutics Board Members (10)

Name Representing Role Since Contact
Info
Bruce Booth Ph.D Atlas Venture Chairman 000 0000
Charles Wilson Ph.D UNUM Therapeutics Co-Founder, Board Member & Chief Executive Officer 000 0000
Dario Campana MD Self Scientific Co-Founder & Chairman 000 0000
Joern Aldag Self Board Member 000 0000
Karen Ferrante MD Self Board Member 000 0000

3 Former Board Members

You’re viewing 5 of 10 board members. Get the full list »